Drug treatment of HIV and AIDS

Hospital Pharmacist

Volumn 8, Issue 4, 2001, Pages

  Davies, E ^a   Morlese, J F ^a   Bower, M ^a   Pozniak, A ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMBINATION CHEMOTHERAPY; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PHENOTYPE; REVIEW; VIRUS RESISTANCE;

EID: 0035003357     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Surrogacy in HIV-1 clinical trials
2. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
5. The Atlantic Study: A randomised, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48-week data
6. Guidelines for the treatment of HIV-infected adults with antiretroviral therapy
7. Functional T-cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
8. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomised equivalence trial
9. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
10. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy
11. Lipodystrophy in patients naive to HIV protease inhibitors
12. Lipids, lipoproteins, triglyceride clearance and cytokines in HIV infection and AIDS
13. A multi-centre, randomised, open-label comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy
14. Switching From a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution
15. Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV positive subjects
16. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
17. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome
18. Correlation between CD4 counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related non-infectious retinal vasculopathy in patients with acquired immunodeficiency syndrome
19. Foscarnet-ganciclovir cytomegalovirus retinitis trial 4: Visual outcomes
20. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine
21. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
22. Complete regression of AIDS-related Kaposi's sarcoma associated human herpes virus-8 during therapy with indinavir
23. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS
24. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma